Qualifying & Developing VEGF Binding Assay using an iQue® Screener PLUS

25th May 2018

Category: Bioanalytical

By: Ben Tyrrell - Scientist, Katie Chapple - Scientist,

The iQue® Screener PLUS, by Intellicyt (part of the Sartorius Group), is used at Sartorius Stedim BioOutsource to achieve a faster assay throughput and deliver an air-gap-deliminated flow of samples to the detectors.

Bevacizumab is a humanized monoclonal antibody (mAb) which mediates its activity through a high affinity binding to VEGF (vascular endothelial growth factor). VEGF is a signalling protein which is involved in the initiation of vasculogenesis and angiogenesis of blood vessels. Due to the reliance of solid tumours on efficient angiogenesis to grow beyond a few mm3 in volume, bevacizumab is used as a combination therapy for a number of malignancies.

By using the latest flow cytometry technology we were able to create an easy-to-use, highly reproducible, and time saving assay specific to bevacizumab. This included using a florescence readout on the iQue® Screener PLUS to quantify the antibody binding, and its specificity was assessed using a range of IgG1 isotype controls.

To find out more about the development method used to qualify this assay, download our scientific poster.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy